AI Chips Today - Certara-NVIDIA Partnership Revolutionizes AI in Drug Development - Yahoo Finance

Certara has partnered with NVIDIA to enhance its AI platform for drug discovery and development by integrating NVIDIA's BioNeMo Agent Toolkit. This collaboration merges Certara's biosimulation softwar... Read original →

The NVIDIA-Certara alliance marks a strategic pivot of AI silicon into life sciences’ core workflows. Technically, BioNeMo’s demand for HBM4 and 3nm-class accelerators will intensify design wins for Micron and Broadcom, while pressuring Taiwan, China-based firms like Skyverse to fast-track CUDA-compatible alternatives. Regulatory scrutiny under the EU AI Act and FDA digital health guidelines will inflate validation costs, pushing biopharma toward geopolitically neutral cloud infrastructures. AMD is countering via MI300X partnerships with Schrödinger, while Apple may leverage HealthKit and wearables for edge-based chronic disease modeling. Within 18 months, AI-powered virtual trials will evolve from optional aids to mandatory regulatory submission components—unlocking a $10B+ market and upending CRO economics.